百奥泰生物科技（广州）有限公司（Bio-Thera Solutions, Ltd）公司致力于研发新一代完全人源抗体和肽类药物，用以治疗危及人类生命的重大疾病, 包括癌症、冠心病、免疫性疾病。目前公司在研产品十余个， 其中公司自主研发的国家1.1 类新药巴替非班已完成Ⅲ期临床研究，正在准备提交上市申请；3个抗体生物类似药药物正在国内外开展临床研究， 1个创新抗体药物偶联物（ADC）正进入I期临床研究，公司另有多个创新抗体候选药物处于临床前研究阶段。公司是广东省自主创新示范企业，承担了国家多项“十二五重大新药创制” 专项、广东省“重大科技专项”等多项国家和省市科研项目，开发了多项新药创制核心关键技术和共性技术。公司开发的新一代抗体药物偶联技术已获得美国专利局4项专利授权。公司开发的哺乳动物细胞抗体生产平台（Threshold ExpreSys），使抗体表达水平达到国际先进水平。公司正在广州建设占地4万平方米、符合国际cGMP标准的抗体药物产业化基地。公司拥有一支学历层次高、专业覆盖面广、技术力量雄厚的人才队伍， 现有员工近200人，拥有硕士和博士学位的比例达50%以上，本科及以上学历80%以上。公司管理和技术核心包括多位资深海外学成归国专家，拥有丰富的生物药物研发和生物技术企业管理经验。公司核心团队成员包括“***”专家、广东省首批“科技领军人才”、广东省“珠江人才计划”创新创业团队等。公司秉承“创新只为生命”的使命，始终以病人的福祉为企业存在的首要核心价值，目标是成为国际上新一代抗体药物研发的引领者。公司现增加多个挑战性的岗位, 当前尤其需要上游工艺，临床科学，产品质量研究，管理等方面高端技术和管理人才。 公司以及当地政府都有对高端技术人才的吸引和优惠政策，欢迎符合条件的有志者加盟。Bio-Thera Solutions Ltd (百奥泰生物科技广州有限公司, www.bio-thera.com ), an emerging biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancers, inflammatory, cardiovascular diseases, and other life threatening conditions. The Company's initial internal products are focused on targets with relative degree of validation and disease areas with proven market opportunities. The company product pipelines include biosimilars and innovative antibodies, with four in clinical trials, one of them with potential becoming best-in-class in late-stage development. With additional multiple candidates in preclinical, a new cGMP facility built for the production of commercial therapeutic antibodies in Guangzhou, the company is sincere and zealous in search and commitment to partnerships. Please contact bd@***@*** if there is interest in exploring potential R&D or commercial collaboration. The company is also looking for leaders in many areas, such as clinical development, process engineer, business development/management to join the senior or executive management team. Bio-Thera provides a competitive benefit package, including company stock. For further inquiry, please con
↓↓↓查看完整介绍↓↓↓
